Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TKCSK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-CLL-1-ds-PBD
|
|||||
| Synonyms |
Anti-CLL-1 ds-PBD
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Anti-CLL-1 THIOMAB Anti-ody
|
Antibody Info | ||||
| Antigen Name |
C-type lectin domain family 12 member A (CLEC12A)
|
Antigen Info | ||||
| Payload Name |
SG2000
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines (IgG light chain K149C site).
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 47.85% (Day 11) | Positive CLL-1 expression (CLL-1+++/++) | ||
| Method Description |
Three human AML cell lines, were used to establish subcutaneous xenograft models for evaluation of anti-CLL-1-ds-PBD efficacy. When mean tumor size reached the desired volume (200 mm3), animals were randomized into groups of n = 8, each with similar mean tumor size. Four hours later, animals in each group were given a single intravenous dose of vehicle or ADC (0.25 mg/kg) through the tail vein.
Click to Show/Hide
|
||||
| In Vivo Model | HL-60 CDX model | ||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 57.73% (Day 14) | Moderate CLL-1 expression (CLL-1++) | ||
| Method Description |
Three human AML cell lines, were used to establish subcutaneous xenograft models for evaluation of anti-CLL-1-ds-PBD efficacy. When mean tumor size reached the desired volume (200 mm3), animals were randomized into groups of n = 8, each with similar mean tumor size. Four hours later, animals in each group were given a single intravenous dose of vehicle or ADC (0.75 mg/kg) through the tail vein.
Click to Show/Hide
|
||||
| In Vivo Model | THP1 CDX model | ||||
| In Vitro Model | Childhood acute monocytic leukemia | THP-1 cells | CVCL_0006 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 72.19% (Day 14) | Moderate CLL-1 expression (CLL-1++) | ||
| Method Description |
Three human AML cell lines, were used to establish subcutaneous xenograft models for evaluation of anti-CLL-1-ds-PBD efficacy. When mean tumor size reached the desired volume (200 mm3), animals were randomized into groups of n = 8, each with similar mean tumor size. Four hours later, animals in each group were given a single intravenous dose of vehicle or ADC (1.5 mg/kg) through the tail vein.
Click to Show/Hide
|
||||
| In Vivo Model | THP1 CDX model | ||||
| In Vitro Model | Childhood acute monocytic leukemia | THP-1 cells | CVCL_0006 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.28% (Day 11) | Positive CLL-1 expression (CLL-1+++/++) | ||
| Method Description |
Three human AML cell lines, were used to establish subcutaneous xenograft models for evaluation of anti-CLL-1-ds-PBD efficacy. When mean tumor size reached the desired volume (200 mm3), animals were randomized into groups of n = 8, each with similar mean tumor size. Four hours later, animals in each group were given a single intravenous dose of vehicle or ADC (0.5 mg/kg) through the tail vein.
Click to Show/Hide
|
||||
| In Vivo Model | HL-60 CDX model | ||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.38% (Day 7) | Positive CLL-1 expression (CLL-1+++/++) | ||
| Method Description |
Three human AML cell lines, were used to establish subcutaneous xenograft models for evaluation of anti-CLL-1-ds-PBD efficacy. When mean tumor size reached the desired volume (200 mm3), animals were randomized into groups of n = 8, each with similar mean tumor size. Four hours later, animals in each group were given a single intravenous dose of vehicle or ADC (0.25 mg/kg) through the tail vein.
Click to Show/Hide
|
||||
| In Vivo Model | EOL-1 CDX model | ||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 87.48% (Day 14) | Moderate CLL-1 expression (CLL-1++) | ||
| Method Description |
Three human AML cell lines, were used to establish subcutaneous xenograft models for evaluation of anti-CLL-1-ds-PBD efficacy. When mean tumor size reached the desired volume (200 mm3), animals were randomized into groups of n = 8, each with similar mean tumor size. Four hours later, animals in each group were given a single intravenous dose of vehicle or ADC (3 mg/kg) through the tail vein.
Click to Show/Hide
|
||||
| In Vivo Model | THP1 CDX model | ||||
| In Vitro Model | Childhood acute monocytic leukemia | THP-1 cells | CVCL_0006 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.88% (Day 7) | Positive CLL-1 expression (CLL-1+++/++) | ||
| Method Description |
Three human AML cell lines, were used to establish subcutaneous xenograft models for evaluation of anti-CLL-1-ds-PBD efficacy. When mean tumor size reached the desired volume (200 mm3), animals were randomized into groups of n = 8, each with similar mean tumor size. Four hours later, animals in each group were given a single intravenous dose of vehicle or ADC (0.5 mg/kg) through the tail vein.
Click to Show/Hide
|
||||
| In Vivo Model | EOL-1 CDX model | ||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.23% (Day 7) | Positive CLL-1 expression (CLL-1+++/++) | ||
| Method Description |
Three human AML cell lines, were used to establish subcutaneous xenograft models for evaluation of anti-CLL-1-ds-PBD efficacy. When mean tumor size reached the desired volume (200 mm3), animals were randomized into groups of n = 8, each with similar mean tumor size. Four hours later, animals in each group were given a single intravenous dose of vehicle or ADC (1 mg/kg) through the tail vein.
Click to Show/Hide
|
||||
| In Vivo Model | EOL-1 CDX model | ||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.90% (Day 11) | Positive CLL-1 expression (CLL-1+++/++) | ||
| Method Description |
Three human AML cell lines, were used to establish subcutaneous xenograft models for evaluation of anti-CLL-1-ds-PBD efficacy. When mean tumor size reached the desired volume (200 mm3), animals were randomized into groups of n = 8, each with similar mean tumor size. Four hours later, animals in each group were given a single intravenous dose of vehicle or ADC (1 mg/kg) through the tail vein.
Click to Show/Hide
|
||||
| In Vivo Model | HL-60 CDX model | ||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 8.00 ng/mL±2.00 ng/mL | Positive CLL-1 expression (CLL-1+++/++) | ||
| Method Description |
Tumor cells were then blocked with excess amount of mouse IgG2a anti-ragweed antibody and treated with ADCs for 6 days at 37°C before cell viability was measured.
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 10.00 ng/mL±2.00 ng/mL | Positive CLL-1 expression (CLL-1+++/++) | ||
| Method Description |
Tumor cells were then blocked with excess amount of mouse IgG2a anti-ragweed antibody and treated with ADCs for 6 days at 37°C before cell viability was measured.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 81.00 ng/mL±9.00 ng/mL | Moderate CLL-1 expression (CLL-1++) | ||
| Method Description |
Tumor cells were then blocked with excess amount of mouse IgG2a anti-ragweed antibody and treated with ADCs for 6 days at 37°C before cell viability was measured.
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | THP-1 cells | CVCL_0006 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.